Efficacy and tolerability of generic pirfenidone after switch from Esbriet® in idiopathic pulmonary fibrosis: a real-world observational study | Synapse
April 19, 2026Open Access
Efficacy and tolerability of generic pirfenidone after switch from Esbriet® in idiopathic pulmonary fibrosis: a real-world observational study
This research aims to evaluate the effects of switching from branded to generic pirfenidone on lung function and tolerability in patients with idiopathic pulmonary fibrosis.
Real-world cohort study design
Involvement of patients with idiopathic pulmonary fibrosis
Comparison of lung function decline and treatment tolerability pre- and post-switch
No clinically meaningful differences in lung function decline after switching
Treatment tolerability remained comparable between branded and generic pirfenidone
Abstract
In this real-world cohort of patients with IPF, switching from branded to generic pirfenidone was not associated with clinically meaningful differences in lung function decline or treatment tolerability.